Cadrenal Therapeutics Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period tocomply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 13, 2026, there were 3,567,592 outstanding shares of common stock, par value $0.001 per share, of CadrenalTherapeutics, Inc. CADRENAL THERAPEUTICS, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026 TABLE OF CONTENTS Item 1.Financial Statements (Unaudited)1Balance Sheets at June30, 2026 and December31, 20251Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2026 and20252Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2026 and 20253Statements of Cash Flows for the Six Months Ended June 30, 2026 and 20255Notes to Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29 Item 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities and Use of Proceeds33Item 3.Defaults Upon Senior Securities33Item 4.Mine Safety Disclosures33Item 5.Other Information33Item 6.Exhibits34 PART I. FINANCIAL INFORMATION CADRENAL THERAPEUTICS, INC.BALANCE SHEETSJune30,2026December31,(unaudited)2025Assets:Current assets:Cash and cash equivalents$2,388,135$4,007,789Receivable from issuance of warrants2,684,904-Interest receivable5,3055,096Prepaid expenses and other current assets410,105200,140Deferred offering costs95,674106,342Total current assets5,584,1234,319,367Property, plant and equipment, net2,6755,174Other assets2,1672,167Total assets$5,588,965$4,326,708Liabilities and Stockholders’ Equity:Current liabilities:Accounts payable$871,913$650,663Accrued liabilities625,344937,319Total current liabilities1,497,2571,587,982Total liabilities1,497,2571,587,982Stockholders’ equity:Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as ofJune30, 2026 and December31, 2025--Common stock, $0.001 par value; 75,000,000 shares authorized, 3,098,592 shares issued andoutstanding as of June 30, 2026; 2,338,127 shares issued and outstanding as of December31, 20253,0982,338Additional paid-in capital48,867,86041,696,533Accumulated deficit(44,779,250)(38,960,145)Total stockholders’ equity4,091,7082,738,726Total liabilities and stockholders’ equity$5,588,965$4,326,708 CADRENAL THERAPEUTICS, INC.STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(unaudited) CADRENAL THERAPEUTICS, INC.STATEMENTS OF CASH FLOWS(unaudited) CADRENAL THERAPEUTICS, INC.Notes to Financial Statements(unaudited) Cadrenal Therapeutics, Inc. (the “Company” or “Cadrenal”) was incorporated on January 25, 2022, in the State of Delaware and isheadquartered in Ponte Vedra, Florida. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specializedtherapies for critical care cardiology and orphan cardiovascular conditions. Its lead program, CAD-1005, is being investigated as afirst-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder, andCardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The Company’s Cardiac Acute Critical Care (CAC